Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Luspatercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Reblozyl

    02 2Reblozyl

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 274

    2019 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 551

    2020 Revenue in Millions : 274

    Growth (%) : 101

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 717

    2021 Revenue in Millions : 551

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Reblozyl

    Luspatercept

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 166

    2021 Revenue in Millions : 17

    Growth (%) : 876

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 1,008

    2022 Revenue in Millions : 717

    Growth (%) : 41

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Reblozyl

    Luspatercept

    arrow
    PharmaVenue
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    PharmaVenue
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 212

    2022 Revenue in Millions : 166

    Growth (%) : 28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF